Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing.

Delivery represents a significant barrier to the clinical advancement of oligonucleotide therapeutics for the treatment of neurological disorders, such as Huntington's disease. Small, endogenous vesicles known as exosomes have the potential to act as oligonucleotide delivery vehicles, but robust and scalable methods for loading RNA therapeutic cargo into exosomes are lacking. Here, we show that hydrophobically modified small interfering RNAs (hsiRNAs) efficiently load into exosomes upon co-incubation, without altering vesicle size distribution or integrity. Exosomes loaded with hsiRNAs targeting Huntingtin mRNA were efficiently internalized by mouse primary cortical neurons and promoted dose-dependent silencing of Huntingtin mRNA and protein. Unilateral infusion of hsiRNA-loaded exosomes, but not hsiRNAs alone, into mouse striatum resulted in bilateral oligonucleotide distribution and statistically significant bilateral silencing of up to 35% of Huntingtin mRNA. The broad distribution and efficacy of hsiRNA-loaded exosomes delivered to brain is expected to advance the development of therapies for the treatment of Huntington's disease and other neurodegenerative disorders.

[1]  Jun Lu,et al.  Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. , 2013, The Journal of allergy and clinical immunology.

[2]  J. Kwekkeboom,et al.  Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi) , 2011, Gut.

[3]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Braeckmans,et al.  Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[6]  S. Gay,et al.  The release of microparticles by apoptotic cells and their effects on macrophages , 2005, Apoptosis.

[7]  M. Wood,et al.  Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. , 2012, Human molecular genetics.

[8]  J. Price,et al.  Human Neural Progenitor Cell Engraftment Increases Neurogenesis and Microglial Recruitment in the Brain of Rats with Stroke , 2012, PloS one.

[9]  A. Khvorova,et al.  Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain , 2015, Molecular therapy. Nucleic acids.

[10]  E. Holzbaur,et al.  Axonal Transport: Cargo-Specific Mechanisms of Motility and Regulation , 2014, Neuron.

[11]  Aled Clayton,et al.  Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.

[12]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[13]  R. Carraway,et al.  Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons , 1995, Neuron.

[14]  D. Sah,et al.  Oligonucleotide therapeutic approaches for Huntington disease. , 2011, The Journal of clinical investigation.

[15]  Cecilia Lässer.  Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors , 2012, Expert opinion on biological therapy.

[16]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  D. Benati,et al.  Exosome derived from murine adipose-derived stromal cells: Neuroprotective effect on in vitro model of amyotrophic lateral sclerosis. , 2016, Experimental cell research.

[18]  Michael S. Levine,et al.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.

[19]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[20]  P. Bevilacqua,et al.  Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure‐specific manner , 2008, RNA.

[21]  Haruhisa Iguchi,et al.  Competitive Interactions of Cancer Cells and Normal Cells via Secretory MicroRNAs* , 2011, The Journal of Biological Chemistry.

[22]  Andrew F. Hill,et al.  Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles , 2014, Journal of extracellular vesicles.

[23]  J. Sinden,et al.  The Development of Stem Cell-Derived Exosomes as a Cell-Free Regenerative Medicine , 2014 .

[24]  J. Rak,et al.  Extracellular Vesicles in Brain Tumor Progression , 2016, Cellular and Molecular Neurobiology.

[25]  Mehmet Fatih Bolukbasi,et al.  Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Crislyn D'Souza-Schorey,et al.  Microvesicles: mediators of extracellular communication during cancer progression , 2010, Journal of Cell Science.

[27]  S. Kaushal,et al.  Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[28]  G. Gerken,et al.  Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. , 2014, International immunology.

[29]  C. Bennett,et al.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. , 2015, Advanced drug delivery reviews.

[30]  L. Shihabuddin,et al.  Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis , 2012, Neuron.

[31]  Lorenzo Silengo,et al.  Extracellular vesicles as an emerging mechanism of cell-to-cell communication , 2012, Endocrine.

[32]  J. Cooper,et al.  Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice , 2014, Movement disorders : official journal of the Movement Disorder Society.

[33]  P. Altevogt,et al.  Exosomes as a potential tool for a specific delivery of functional molecules. , 2013, Methods in molecular biology.

[34]  Martin Hintersteiner,et al.  The rough endoplasmatic reticulum is a central nucleation site of siRNA-mediated RNA silencing , 2013, The EMBO journal.

[35]  I. Sariyer.  Transfection of neuronal cultures. , 2013, Methods in molecular biology.

[36]  T. D. de Gruijl,et al.  Functional delivery of viral miRNAs via exosomes , 2010, Proceedings of the National Academy of Sciences.

[37]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[38]  J. Leonard,et al.  FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver , 2013, Pharmaceuticals.

[39]  I. Sargent,et al.  Exosome-mediated delivery of siRNA in vitro and in vivo , 2012, Nature Protocols.

[40]  Shinobu Ueda,et al.  Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  R. Schiffelers,et al.  Exosome mimetics: a novel class of drug delivery systems , 2012, International journal of nanomedicine.

[42]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[43]  Jessica A. Weber,et al.  Export of microRNAs and microRNA-protective protein by mammalian cells , 2010, Nucleic acids research.

[44]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[45]  Elena Cattaneo,et al.  Loss of normal huntingtin function: new developments in Huntington's disease research , 2001, Trends in Neurosciences.

[46]  Y. Imai,et al.  A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. , 1996, Biochemical and biophysical research communications.

[47]  D Michiel Pegtel,et al.  Exosomes: Fit to deliver small RNA. , 2010, Communicative & integrative biology.

[48]  M. Wood,et al.  Exosomes for targeted siRNA delivery across biological barriers. , 2013, Advanced drug delivery reviews.